Hand tumorsare many and varied, although benign tumors are common. The pathology and histology of these tumors are not unlike these characteristics of the tumor when it occurs elsewhere. Early diagnosis and proper treatment of all hand tumors have been emphasized since the growth of tumors and pain can cause disturbance of intrinsic function of the hand. For the period of 10 years from 1977 to 1986, 105 cases of hand tumor were treated surgically and the results of clinical observation were as follows ; l. Among 105 cases, benign tumor was 101 cases(96.2%) Bone origin tumor was 20 cases, in which enchondroma and enchondromatosis were 17 cases(70%). Soft tissue origin tumor was 85 cases, in which ganglion was 54 cases(63.5%). 2. Among 105 cases, 42 cases were male and 63 cases were female. In age distribution, it showed even distribution. 3. In the duration of wymptom, 51 cases were below 1 year(48.6%). 4. The tumor occured 85 cases in soft tissue, 14 in phalanx, 7 in metacarpal and 1 in carpal bone. 5. The tumors were treated by excision or curettage and bone graft with good improvement, but postoperatively recurred in 2 cases of Hemangioma. Ampuation was performed in 3 cases of malignant tumors without recurrence.
Age Distribution ; Carpal Bones ; Chondroma ; Clinical Study ; Curettage ; Early Diagnosis ; Enchondromatosis ; Female ; Ganglion Cysts ; Hand ; Hemangioma ; Humans ; Male ; Pathology ; Recurrence ; Transplants

As South Korea becomes a super-aged society by 2025, the number of patients with Parkinson’s disease (PD) is increasing rapidly. PD is characterized by motor symptoms, such as bradykinesia, tremor, and rigidity, and non-motor symptoms, such as depression, cognitive impairment, and autonomic nervous system disorders. The pathophysiology of dysphagia in PD is a complex interplay of motor disorders caused by dopamine deficiency in the basal ganglia and the involvement of the brainstem swallowing center and the peripheral nerve system affected by the PD pathology. Dysphagia in PD presents difficulties in taking medications, contributes to malnutrition and dehydration, and reduces the overall quality of life. Despite dysphagia being a prevalent problem in PD, a significant number of patients remain unaware of the swallowing difficulties. Therefore, healthcare practitioners need to understand dysphagia in PD, consider early screening and objective evaluations, and proactively implement swallowing treatment and compensatory therapy as needed. This review examines the pathophysiology, clinical characteristics, screening and diagnosis, and severity assessment of dysphagia in PD.

As South Korea becomes a super-aged society by 2025, the number of patients with Parkinson’s disease (PD) is increasing rapidly. PD is characterized by motor symptoms, such as bradykinesia, tremor, and rigidity, and non-motor symptoms, such as depression, cognitive impairment, and autonomic nervous system disorders. The pathophysiology of dysphagia in PD is a complex interplay of motor disorders caused by dopamine deficiency in the basal ganglia and the involvement of the brainstem swallowing center and the peripheral nerve system affected by the PD pathology. Dysphagia in PD presents difficulties in taking medications, contributes to malnutrition and dehydration, and reduces the overall quality of life. Despite dysphagia being a prevalent problem in PD, a significant number of patients remain unaware of the swallowing difficulties. Therefore, healthcare practitioners need to understand dysphagia in PD, consider early screening and objective evaluations, and proactively implement swallowing treatment and compensatory therapy as needed. This review examines the pathophysiology, clinical characteristics, screening and diagnosis, and severity assessment of dysphagia in PD.

As South Korea becomes a super-aged society by 2025, the number of patients with Parkinson’s disease (PD) is increasing rapidly. PD is characterized by motor symptoms, such as bradykinesia, tremor, and rigidity, and non-motor symptoms, such as depression, cognitive impairment, and autonomic nervous system disorders. The pathophysiology of dysphagia in PD is a complex interplay of motor disorders caused by dopamine deficiency in the basal ganglia and the involvement of the brainstem swallowing center and the peripheral nerve system affected by the PD pathology. Dysphagia in PD presents difficulties in taking medications, contributes to malnutrition and dehydration, and reduces the overall quality of life. Despite dysphagia being a prevalent problem in PD, a significant number of patients remain unaware of the swallowing difficulties. Therefore, healthcare practitioners need to understand dysphagia in PD, consider early screening and objective evaluations, and proactively implement swallowing treatment and compensatory therapy as needed. This review examines the pathophysiology, clinical characteristics, screening and diagnosis, and severity assessment of dysphagia in PD.

As South Korea becomes a super-aged society by 2025, the number of patients with Parkinson’s disease (PD) is increasing rapidly. PD is characterized by motor symptoms, such as bradykinesia, tremor, and rigidity, and non-motor symptoms, such as depression, cognitive impairment, and autonomic nervous system disorders. The pathophysiology of dysphagia in PD is a complex interplay of motor disorders caused by dopamine deficiency in the basal ganglia and the involvement of the brainstem swallowing center and the peripheral nerve system affected by the PD pathology. Dysphagia in PD presents difficulties in taking medications, contributes to malnutrition and dehydration, and reduces the overall quality of life. Despite dysphagia being a prevalent problem in PD, a significant number of patients remain unaware of the swallowing difficulties. Therefore, healthcare practitioners need to understand dysphagia in PD, consider early screening and objective evaluations, and proactively implement swallowing treatment and compensatory therapy as needed. This review examines the pathophysiology, clinical characteristics, screening and diagnosis, and severity assessment of dysphagia in PD.

No abstract available.

The antihypertensive effects of diltiazem was observed in 30 cases of essential hypertension, and following results were obtained. 1) Mean decrease in systolic and diastolic blood pressure by oral diltiazem was 42.0+/-2.5mmHg and 17.8+/-1.7mmHg. The results of antihypertensive therapy revealed good control in 50% fair control in 30% poor in 17% and failure in 3% of the cases. In 80% of the cases, good or fair control of Hypertension which means drop of diastolic pressure to the level of less than 100mmhg was observed. 2) Mean drop in heart rate was 21+/-2 beats/min. 3) Daily dose was 90-180mg. 4) The side effect of oral Diltiazem was mild headache and dizziness, respectively one case.
Blood Pressure ; Diltiazem* ; Dizziness ; Headache ; Heart Rate ; Hypertension

Parkinson's disease (PD) is a neurodegenerative disorder characterized by typical motor symptoms such as resting tremor, bradykinesia, and rigidity, as well as non-motor manifestations, including psychiatric symptoms, autonomic dysfunction, and cognitive impairment. These symptoms induce a marked impact on functional independence in daily activities and quality of life in PD patients. Recent guidelines recommend adequate rehabilitation education and treatment from the early stages of PD, and rehabilitation has become part of standard care for PD. In Korea, the number of patients with PD has more than tripled over 15 years, from 39,265 in 2004 to 125,607 in 2019. However, the rehabilitation usage of PD patients has not changed remarkably, and it remains suboptimal in Korea compared to several developed countries, which have advanced and disseminated guidelines and implemented specialized care delivery systems for PD over the past 20 years. Additional efforts are warranted to provide adequate rehabilitation therapies for PD patients in Korea.

Coenzyme Q is concentrated in Golgi apparatus membranes and mitochondria, but not in other membranes. Although it is difficult to prove the metabolic action of coenzyme Q administered exogenously in clinical cases, the effect of this substance can be evaluated by criteria based on clinical findings. In an attempt to evaluate the effect of coenzyme Q for the treatment of 67 patients(male 26 cases, female 41 cases) of congestive heart failure, we administered Coenzyme Q1030mg daily for 4 to 8 weeks. Most of them were valvular heart disease(74.6%) and hypertension (14.9%). Clinical effects were evaluated at least 4 weeks later by the criteria using a scoring method of severity of congestive heart failure which was devised by Ishiyama, etc. In summary, a definite effect was found in 13 cases(19%) and a mild effect was observed in 46 cases(69%). During treatment there were no significant side effects, and also no significant changes in heart rate and blood pressure.
Blood Pressure ; Estrogens, Conjugated (USP)* ; Female ; Golgi Apparatus ; Heart ; Heart Failure* ; Heart Rate ; Humans ; Hypertension ; Membranes ; Mitochondria ; Research Design ; Ubiquinone

BACKGROUND: Diabetic ketoacidosis(DKA) is serious acute metabolic complication and the most important cause of high morbidity and mortality of diabetes. The object of this study is to examine the clinical characteristics of patients with DKA who had a prior history of diabetes or not. METHOD: Authors reviewed retrospectively the medical records of 49 cases adimitted to Kyungpook National University Hospital from January 1991 to June 1997 with a diagnosis of DKA and classified cases as type I, type II and newly diagnosed diabetics according to prior history of diabetes. RESULTS: 1. Of 49 cases of DKA, 24(49%) were classified as type I, 17(35%) as type II from data available in the medical records, and 8(16%) had DKA as the initial manifestation of the disease. 2. The male to female ratio was 0.5 : 1 in type I, 1.1 : 1 in type II and 1.7 : 1 in newly diagnosed diabetics, and the mean age was 24.4 in type I, 57.9 in type II and 23.9 years old in newly diagnosed diabetics. 3. The mean duration between initial diagnosis of diabetes and the occurrence of DKA was 2.6 in type I and 6.9 years in type II diabetes. The occurrence of DKA within 2 years of initial diagnosis of diabetes was 54% in type I and 18% in type II diabetes, but the occurrence of DKA after 5 years of initial diagnosis of diabetes was 17% in type I and 47% in type II diabetes. 4. The precipitating factors of DKA were identified in 88% in type I, 76% in type II and 38% in newly diagnosed diabetics, and the most common precipitating factor was omission of treatment in both type I and type II(type I: 56%, type II: 35%). 5. The altered mental status was correlated with increased osmolality (p<0.05), but not with other laboratory values such as pH, bicabonate, glucose, anion gap and dehydration status(p>0.05). CONCLUSION: It is necessary to conduct early aggressive evaluation for early diagnosis and proper treatment of DKA, because DKA occurs in patients with prior history of type II diabetes and without prior diabetic history as well as patients with prior history of type I diabetes.
Acid-Base Equilibrium ; Dehydration ; Diagnosis ; Early Diagnosis ; Female ; Glucose ; Gyeongsangbuk-do ; Humans ; Hydrogen-Ion Concentration ; Male ; Medical Records ; Mortality ; Osmolar Concentration ; Precipitating Factors ; Retrospective Studies